3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Neuroendocrine Tumors
6
Gastro-enteropancreatic neuroendocrine tumor
2
Carcinoid Tumor
2
Serotonin Syndrome
1
Prostatic Neoplasms
1
Peritoneal Neoplasms
1
Neuroendocrine Tumour With Carcinoid Symptoms
1
Neuroendocrine Tumors in Lung
1
Intestinal Obstruction
1
Flushing
1
Endocrine Tumors
1
Diarrhea
1
Carcinoma
1
Adenoma, Islet Cell
1
Acromegaly
1
Interventions
Sunitinib
4
Everolimus
4
Endoscopic Ultrasound-Guided Fine Needle Aspiration
2
napabucasin
1
lanreotide
1
irinotecan sucrosofate
1
belzutifan
1
Taxes
1
Paclitaxel
1
Oxaliplatin
1
Octreotide
1
Leucovorin
1
LY2940680
1
Irinotecan
1
Gemcitabine
1
Fluorouracil
1
Albumin-Bound Paclitaxel
1
90Y-octreotide, DOTA-Tyr(3)-
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Adenoma, Islet Cell
×
lanreotide
×
Clear all
NCT05477576
2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3
Recruiting
338 enrolled